News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘OvarianCancer’ clear

  • A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, scientists from Dana-Farber report.

Tags: LungCancer, OvarianCancer

  • On Sept. 6 at Boston City Hall Plaza, Dana-Farber/Brigham and Women's Cancer Center, along with a coalition of six organizations, launched a month-long campaign to promote ovarian cancer awareness. The group, known as OvarianCancerAwareness.org, is dedicated to educating the public about the subtle symptoms of ovarian cancer to promote early detection.

Tags: OvarianCancer

  • One of the shortcomings of a therapy that uses millions of identical antibodies to boost the immune system's attack on cancer cells is that many patients whose tumors recede in response to the treatment also experience serious inflammatory problems, such as severe diarrhea and rashes. In a new study, a team led by Dana-Farber Cancer Institute researchers shows that giving periodic infusions of such "monoclonal" antibodies to patients who have received a widely used cancer vaccine unleashes a strong immune response to tumors, with less-harsh side effects.

Tags: Melanoma, OvarianCancer, TargetedTherapy

  • Dana-Farber/Brigham and Women's Cancer Center has joined forces with the Massachusetts Chapter of the National Ovarian Cancer Coalition and The M. Patricia Cronin Foundation to launch a month-long campaign to promote ovarian cancer awareness.

Tags: OvarianCancer

  • A "watch and wait" strategy reduces the need for unnecessary chemo in young girls, which can lead to secondary cancers and other health issues later in life.

Tags: ChildhoodCancer, OvarianCancer, PatientEducation

  • A new Dana-Farber Cancer Institute study suggests there is a direct connection between high-grade serous ovarian cancer (HGSOC) and fallopian tubes. The finding could aid in the development of better treatments for the cancer.

Tags: OvarianCancer, GynecologicCancers

  • Dana-Farber researchers have demonstrated a molecular strategy that they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.

Tags: BreastCancer, OvarianCancer, GynecologicCancers

  • As part of Project Achilles, aimed at finding the "Achilles heel" of cancer, researchers from Dana-Farber Cancer Institute, Harvard and the Broad Institute of MIT examined cells from over 100 tumors, including 25 ovarian cancer tumors, finding promising new targets for genetic research.

Tags: BasicResearch, OvarianCancer, GynecologicCancers

  • The discovery of a subtype of ovarian cancer that could account for up to one-third of all serous ovarian cancers may lead to clinical trials using anti-angiogenic drugs that are already being tested in other cancers.

Tags: OvarianCancer, GynecologicCancers

  • Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

Tags: BasicResearch, BreastCancer, Genomics, OvarianCancer, GynecologicCancers

Showing 1-10 of 18 items